echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA Grants MB-102 (CD123 CAR-T) Orphan Drug For BPDCN

    FDA Grants MB-102 (CD123 CAR-T) Orphan Drug For BPDCN

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, Mustang Bio
    (http:// announcedthat the u.SFood andDrug(http://Administration (
    FDA(http://) has granted MB-102 (CD123 CAR-T) the status of orphan drug for the treatment of parent plasma cell protrusion cell tumors (BPDCN)about MB-102
    MB-102 is a CAR-T cell therapy that targets CD123 to identify and eliminate tumor cells expressing CD123 by engineering patient T cellsCD123 is widely expressed on the surface of bone marrow cells in patients with bone marrow hyperplasia syndrome, but also in a variety of blood system malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hair cell leukemia, BPDCN, chronic myeloid leukemia, Hodgkin lymphoma, etcElzonris
    Elzonris is a CD123-guided cytotoxin designed specifically for CD123 targets, a drug combined with a recombinant of human IL-3 with amputated diphtheria toxin (DT), and the IL-3 structural domain is able to direct cytotoxic DT fragments to tumor cells that express CD123After internalizing tumor cells, Elzonris is able to irreversibly inhibit the proteinsynthetic(http://and induce target apoptosisin the U.S., Elzonris has been granted Breakthrough Drug Qualification (BTD), Orphan Drug Qualification (ODD), and approved through the FDA's priority review processIn the EU, Elzonris has been granted accelerated approval, which is expected to be approved in the first quarter of 2019, Stemline is also evaluating Elzonris for treatment of other indications, including chronic bone marrow monocytocytic leukemia (CMML), bone marrow fibrosis (MF), and other indications
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.